Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: Focus on the role of hypocretin and melatonin

Ageing Research Reviews

Volumn 12, Issue 1, 2013, Pages 188-200

  Slats, Diane ^a,b   Claassen, Jurgen A H R ^a,b   Verbeek, Marcel M ^a   Overeem, Sebastiaan ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Circadian rhythm; Dementia; Hypocretin; Melatonin; Sleep disorders

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; G PROTEIN COUPLED RECEPTOR; GALANTAMINE; HALOPERIDOL; HYPNOTIC AGENT; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; OREXIN; OREXIN A; OREXIN B; PLACEBO; PSYCHOSTIMULANT AGENT; RIVASTIGMINE; SEDATIVE AGENT; TAU PROTEIN; ZOLPIDEM;

AGED; AGING; ALZHEIMER DISEASE; APOPTOSIS; BEDTIME DOSAGE; BRAIN STEM; CEREBROSPINAL FLUID LEVEL; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; ELECTRON MICROSCOPY; ENTORHINAL CORTEX; EXERCISE; FOREBRAIN; HIPPOCAMPUS; HUMAN; HYPERSOMNIA; HYPOTHALAMUS; INSOMNIA; MEMORY; META ANALYSIS (TOPIC); NARCOLEPSY; NEUROENDOCRINE SYSTEM; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONSET AGE; PATHOPHYSIOLOGY; PHOTOTHERAPY; POLYSOMNOGRAPHY; PREOPTIC NUCLEUS; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; REVIEW; SLEEP; SLEEP DISORDER; SLEEP WAKING CYCLE; SUPRACHIASMATIC NUCLEUS; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CIRCADIAN RHYTHM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELATONIN; NEUROPEPTIDES; SLEEP; SLEEP DISORDERS;

EID: 84867479772     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2012.04.003     Document Type: Review

References (186)

1. Adamantidis A.R., Zhang F., Aravanis A.M., Deisseroth K., de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007, 450:420-424.
2. Ancoli-Israel S., Gehrman P., Martin J.L., Shochat T., Marler M., Corey-Bloom J., Levi L. Increased light exposure consolidates sleep and strengthens circadian rhythms in severe Alzheimer's disease patients. Behavioral Sleep Medicine 2003, 1:22-36.
3. Ancoli-Israel S., Klauber M.R., Gillin J.C., Campbell S.S., Hofstetter C.R. Sleep in non-institutionalized Alzheimer's disease patients. Aging 1994, 6:451-458.
4. Ancoli-Israel S., Klauber M.R., Jones D.W., Kripke D.F., Martin J., Mason W., Pat-Horenczyk R., Fell R. Variations in circadian rhythms of activity, sleep, and light exposure related to dementia in nursing-home patients. Sleep 1997, 20:18-23.
5. Ancoli-Israel S., Martin J.L., Kripke D.F., Marler M., Klauber M.R. Effect of light treatment on sleep and circadian rhythms in demented nursing home patients. Journal of the American Geriatrics Society 2002, 50:282-289.
6. Appelbaum L., Wang G., Yokogawa T., Skariah G.M., Smith S.J., Mourrain P., Mignot E. Circadian and homeostatic regulation of structural synaptic plasticity in hypocretin neurons. Neuron 2010, 68:87-98.
7. Appelbaum L., Wang G.X., Maro G.S., Mori R., Tovin A., Marin W., Yokogawa T., Kawakami K., Smith S.J., Gothilf Y., Mignot E., Mourrain P. Sleep-wake regulation and hypocretin-melatonin interaction in zebrafish. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:21942-21947.
8. Arendt J., Skene D.J., Middleton B., Lockley S.W., Deacon S. Efficacy of melatonin treatment in jet lag, shift work, and blindness. Journal of Biological Rhythms 1997, 12:604-617.
9. Asayama K., Yamadera H., Ito T., Suzuki H., Kudo Y., Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. Journal of Nippon Medical School 2003, 70:334-341.
10. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
11. Baumann C.R., Hersberger M., Bassetti C.L. Hypocretin-1 (orexin A) levels are normal in Huntington's disease. Journal of Neurology 2006, 253:1232-1233.
12. Benarroch E.E. Suprachiasmatic nucleus and melatonin: reciprocal interactions and clinical correlations. Neurology 2008, 71:594-598.
13. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.M., Holtzman D.M. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nature Neuroscience 2011, 14:750-756.
14. Bianchetti A., Scuratti A., Zanetti O., Binetti G., Frisoni G.B., Magni E., Trabucchi M. Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after discharge from an Alzheimer dementia unit. Dementia 1995, 6:108-112.
15. Blanks J.C., Schmidt S.Y., Torigoe Y., Porrello K.V., Hinton D.R., Blanks R.H. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiology of Aging 1996, 17:385-395.
16. Blanks J.C., Torigoe Y., Hinton D.R., Blanks R.H. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiology of Aging 1996, 17:377-384.
17. Bliwise D.L. Sleep apnea APOE4 and Alzheimer's disease 20 years and counting?. Journal of Psychosomatic Research 2002, 53:539-546.
18. Bliwise D.L., Tinklenberg J., Yesavage J.A., Davies H., Pursley A.M., Petta D.E., Widrow L., Guilleminault C., Zarcone V.P., Dement W.C. REM latency in Alzheimer's disease. Biological Psychiatry 1989, 25:320-328.
19. Bonanni E., Maestri M., Tognoni G., Fabbrini M., Nucciarone B., Manca M.L., Gori S., Iudice A., Murri L. Daytime sleepiness in mild and moderate Alzheimer's disease and its relationship with cognitive impairment. Journal of Sleep Research 2005, 14:311-317.
20. Bondareff W., Mountjoy C.Q., Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982, 32:164-168.
21. Bonnavion P., de Lecea L. Hypocretins in the control of sleep and wakefulness. Current Neurology and Neuroscience Reports 2010, 10:174-179.
22. Bourgin P., Huitron-Resendiz S., Spier A.D., Fabre V., Morte B., Criado J.R., Sutcliffe J.G., Henriksen S.J., de Lecea L. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. Journal of Neuroscience 2000, 20:7760-7765.
23. Bozner P., Grishko V., LeDoux S.P., Wilson G.L., Chyan Y.C., Pappolla M.A. The amyloid beta protein induces oxidative damage of mitochondrial DNA. Journal of Neuropathology and Experimental Neurology 1997, 56:1356-1362.
24. Braak H., Braak E. Alzheimer's disease affects limbic nuclei of the thalamus. Acta Neuropathologica 1991, 81:261-268.
25. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991, 82:239-259.
26. Brismar K., Hylander B., Eliasson K., Rossner S., Wetterberg L. Melatonin secretion related to side-effects of beta-blockers from the central nervous system. Acta Medica Scandinavica 1988, 223:525-530.
27. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers & Dementia 2007, 3:186-191.
28. Burns A., Allen H., Tomenson B., Duignan D., Byrne J. Bright light therapy for agitation in dementia: a randomized controlled trial. International Psychogeriatrics 2009, 21:711-721.
29. Campbell S.S., Kripke D.F., Gillin J.C., Hrubovcak J.C. Exposure to light in healthy elderly subjects and Alzheimer's patients. Physiology and Behavior 1988, 42:141-144.
30. Cardinali D.P., Brusco L.I., Liberczuk C., Furio A.M. The use of melatonin in Alzheimer's disease. Neuroendocrinology Letters 2002, 23(Suppl. 1):20-23.
31. Cardinali D.P., Furio A.M., Brusco L.I. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Current Neuropharmacology 2010, 8:218-227.
32. Cardinali D.P., Golombek D.A. The rhythmic GABAergic system. Neurochemical Research 1998, 23:607-614.
33. Cardinali D.P., Rita M.N., Pereyra E., Solveyra C.G. Role of prostaglandins in rat pineal neuroeffector junction. Changes in melatonin and norepinephrine release in vitro. Endocrinology 1982, 111:530-534.
34. Carvalho-Bos S.S., Riemersma-van der Lek R.F., Waterhouse J., Reilly T., Van Someren E.J. Strong association of the rest-activity rhythm with well-being in demented elderly women. American Journal of Geriatric Psychiatry 2007, 15:92-100.
35. Cassone V.M., Chesworth M.J., Armstrong S.M. Entrainment of rat circadian rhythms by daily injection of melatonin depends upon the hypothalamic suprachiasmatic nuclei. Physiology and Behavior 1986, 36:1111-1121.
36. Chou T.C., Bjorkum A.A., Gaus S.E., Lu J., Scammell T.E., Saper C.B. Afferents to the ventrolateral preoptic nucleus. Journal of Neuroscience 2002, 22:977-990.
37. Chou T.C., Scammell T.E., Gooley J.J., Gaus S.E., Saper C.B., Lu J. Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms. Journal of Neuroscience 2003, 23:10691-10702.
38. Chun W., Johnson G.V. The role of tau phosphorylation and cleavage in neuronal cell death. Frontiers in Bioscience 2007, 12:733-756.
39. Colenda C.C., Cohen W., McCall W.V., Rosenquist P.B. Phototherapy for patients with Alzheimer disease with disturbed sleep patterns: results of a community-based pilot study. Alzheimer Disease and Associated Disorders 1997, 11:175-178.
40. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L., Gautvik V.T., Bartlett F.S., Frankel W.N., van den Pol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:322-327.
41. Deng Y.Q., Xu G.G., Duan P., Zhang Q., Wang J.Z. Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacologica Sinica 2005, 26:519-526.
42. Dowling G.A., Burr R.L., Van Someren E.J., Hubbard E.M., Luxenberg J.S., Mastick J., Cooper B.A. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. Journal of the American Geriatrics Society 2008, 56:239-246.
43. Dowling G.A., Hubbard E.M., Mastick J., Luxenberg J.S., Burr R.L., Van Someren E.J. Effect of morning bright light treatment for rest-activity disruption in institutionalized patients with severe Alzheimer's disease. International Psychogeriatrics 2005, 17:221-236.
44. Dowling G.A., Mastick J., Hubbard E.M., Luxenberg J.S., Burr R.L. Effect of timed bright light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 2005, 20:738-743.
45. Fabris C., Cozzi B., Hay-Schmidt A., Naver B., Moller M. Demonstration of an orexinergic central innervation of the pineal gland of the pig. Journal of Comparative Neurology 2004, 471:113-127.
46. Feng Z., Qin C., Chang Y., Zhang J.T. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radical Biology and Medicine 2006, 40:101-109.
47. Feng Z., Zhang J.T. Melatonin reduces amyloid beta-induced apoptosis in pheochromocytoma (PC12) cells. Journal of Pineal Research 2004, 37:257-266.
48. Ferrari E., Arcaini A., Gornati R., Pelanconi L., Cravello L., Fioravanti M., Solerte S.B., Magri F. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Experimental Gerontology 2000, 35:1239-1250.
49. Friedland R.P., Luxenberg J.S., Koss E. A quantitative study of intracranial calcification in dementia of the Alzheimer type. International Psychogeriatrics 1990, 2:36-43.
50. Friedman L.F., Zeitzer J.M., Lin L., Hoff D., Mignot E., Peskind E.R., Yesavage J.A. In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 2007, 68:793-794.
51. Fronczek R., Baumann C.R., Lammers G.J., Bassetti C.L., Overeem S. Hypocretin/orexin disturbances in neurological disorders. Sleep Medicine Reviews 2009, 13:9-22.
52. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease. Brain 2008, 131:e88.
53. Fronczek R., van Geest S., Frolich M., Overeem S., Roelandse F.W., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiology of Aging 2011, (Epub ahead of print).
54. Gagnon J.F., Petit D., Fantini M.L., Rompre S., Gauthier S., Panisset M., Robillard A., Montplaisir J. REM sleep behavior disorder and REM sleep without atonia in probable Alzheimer disease. Sleep 2006, 29:1321-1325.
55. Garzon C., Guerrero J.M., Aramburu O., Guzman T. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. Aging Clinical and Experimental Research 2009, 21:38-42.
56. Gehrman P., Marler M., Martin J.L., Shochat T., Corey-Bloom J., Ancoli-Israel S. The timing of activity rhythms in patients with dementia is related to survival. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2004, 59:1050-1055.
57. Gehrman P.R., Martin J.L., Shochat T., Nolan S., Corey-Bloom J., Ancoli-Israel S. Sleep-disordered breathing and agitation in institutionalized adults with Alzheimer disease. American Journal of Geriatric Psychiatry 2003, 11:426-433.
58. Gerdin M.J., Masana M.I., Rivera-Bermudez M.A., Hudson R.L., Earnest D.J., Gillette M.U., Dubocovich M.L. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB Journal 2004, 18:1646-1656.
59. Goedert M., Spillantini M.G., Crowther R.A. Tau proteins and neurofibrillary degeneration. Brain Pathology 1991, 1:279-286.
60. Grady S.P., Nishino S., Czeisler C.A., Hepner D., Scammell T.E. Diurnal variation in CSF orexin-A in healthy male subjects. Sleep 2006, 29:295-297.
61. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005, 27:119-130.
62. Harper D.G., Volicer L., Stopa E.G., McKee A.C., Nitta M., Satlin A. Disturbance of endogenous circadian rhythm in aging and Alzheimer disease. American Journal of Geriatric Psychiatry 2005, 13:359-368.
63. Holsboer-Trachsler E., Hatzinger M., Stohler R., Hemmeter U., Gray J., Muller J., Kocher R., Spiegel R. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology 1993, 8:87-92.
64. Jang M.H., Jung S.B., Lee M.H., Kim C.J., Oh Y.T., Kang I., Kim J., Kim E.H. Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells. Neuroscience Letters 2005, 380:26-31.
65. Jansen S.L., Forbes D.A., Duncan V., Morgan D.G. Melatonin for cognitive impairment. Cochrane Database of Systematic Reviews 2006, CD003802.
66. Jin X., Shearman L.P., Weaver D.R., Zylka M.J., de Vries G.J., Reppert S.M. A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 1999, 96:57-68.
67. Johnson R.F., Moore R.Y., Morin L.P. Loss of entrainment and anatomical plasticity after lesions of the hamster retinohypothalamic tract. Brain Research 1988, 460:297-313.
68. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Fujiki N., Nishino S., Holtzman D.M. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
69. Katz B., Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Survey of Ophthalmology 1989, 34:31-43.
70. Kondo K., Niino M., Shido K. A case-control study of Alzheimer's disease in Japan--significance of life-styles. Dementia 1994, 5:314-326.
71. Lack L.C., Wright H.R. Chronobiology of sleep in humans. Cellular and Molecular Life Sciences 2007, 64:1205-1215.
72. Lahiri D.K. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. Journal of Pineal Research 1999, 26:137-146.
73. Lahiri D.K., Chen D., Ge Y.W., Bondy S.C., Sharman E.H. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. Journal of Pineal Research 2004, 36:224-231.
74. Lebert F., Pasquier F., Petit H. Behavior assessment in Alzheimer type dementia using the disruptive behavior questionnaire. Presse Medicale 1996, 25:665-667.
75. Lee J.H., Bliwise D.L., Ansari F.P., Goldstein F.C., Cellar J.S., Lah J.J., Levey A.I. Daytime sleepiness and functional impairment in Alzheimer disease. American Journal of Geriatric Psychiatry 2007, 15:620-626.
76. Leston J., Harthe C., Brun J., Mottolese C., Mertens P., Sindou M., Claustrat B. Melatonin is released in the third ventricle in humans. A study in movement disorders. Neuroscience Letters 2010, 469:294-297.
77. Li X.C., Wang Z.F., Zhang J.X., Wang Q., Wang J.Z. Effect of melatonin on calyculin A-induced tau hyperphosphorylation. European Journal of Pharmacology 2005, 510:25-30.
78. Little J.T., Satlin A., Sunderland T., Volicer L. Sundown syndrome in severely demented patients with probable Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 1995, 8:103-106.
79. Liu H.C., Hong C.J., Wang S.J., Fuh J.L., Wang P.N., Shyu H.Y., Teng E.L. ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults. Neurology 1999, 53:962-966.
80. Liu R.Y., Zhou J.N., Hoogendijk W.J., van Heerikhuize J., Kamphorst W., Unmehopa U.A., Hofman M.A., Swaab D.F. Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. Journal of Neuropathology and Experimental Neurology 2000, 59:314-322.
81. Lyketsos C.G., Lindell Veiel L., Baker A., Steele C. A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. International Journal of Geriatric Psychiatry 1999, 14:520-525.
82. Macchi M.M., Bruce J.N. Human pineal physiology and functional significance of melatonin. Frontiers in Neuroendocrinology 2004, 25:177-195.
83. Mahlberg R., Walther S. Actigraphy in agitated patients with dementia. Monitoring treatment outcomes. Zeitschrift fur Gerontologie und Geriatrie 2007, 40:178-184.
84. Marcus J.N., Aschkenasi C.J., Lee C.E., Chemelli R.M., Saper C.B., Yanagisawa M., Elmquist J.K. Differential expression of orexin receptors 1 and 2 in the rat brain. Journal of Comparative Neurology 2001, 435:6-25.
85. Martin J., Marler M., Shochat T., Ancoli-Israel S. Circadian rhythms of agitation in institutionalized patients with Alzheimer's disease. Chronobiology International 2000, 17:405-418.
86. Matsubara E., Bryant-Thomas T., Pacheco Quinto J., Henry T.L., Poeggeler B., Herbert D., Cruz-Sanchez F., Chyan Y.J., Smith M.A., Perry G., Shoji M., Abe K., Leone A., Grundke-Ikbal I., Wilson G.L., Ghiso J., Williams C., Refolo L.M., Pappolla M.A., Chain D.G., Neria E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Journal of Neurochemistry 2003, 85:1101-1108.
87. McCurry S.M., Logsdon R.G., Teri L., Gibbons L.E., Kukull W.A., Bowen J.D., McCormick W.C., Larson E.B. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. Journal of Geriatric Psychiatry and Neurology 1999, 12:53-59.
88. McCurry S.M., Pike K.C., Vitiello M.V., Logsdon R.G., Larson E.B., Teri L. Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer's disease: results of a randomized, controlled trial. Journal of the American Geriatrics Society 2011, 59:1393-1402.
89. McIntyre I.M., Burrows G.D., Norman T.R. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. Biological Psychiatry 1988, 24:108-112.
90. Mikkelsen J.D., Hauser F., deLecea L., Sutcliffe J.G., Kilduff T.S., Calgari C., Pevet P., Simonneaux V. Hypocretin (orexin) in the rat pineal gland: a central transmitter with effects on noradrenaline-induced release of melatonin. European Journal of Neuroscience 2001, 14:419-425.
91. Mishima K., Tozawa T., Satoh K., Matsumoto Y., Hishikawa Y., Okawa M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biological Psychiatry 1999, 45:417-421.
92. Monteleone P., Forziati D., Orazzo C., Maj M. Preliminary observations on the suppression of nocturnal plasma melatonin levels by short-term administration of diazepam in humans. Journal of Pineal Research 1989, 6:253-258.
93. Montplaisir J., Petit D., Lorrain D., Gauthier S., Nielsen T. Sleep in Alzheimer's disease: further considerations on the role of brainstem and forebrain cholinergic populations in sleep-wake mechanisms. Sleep 1995, 18:145-148.
94. Moran M., Lynch C.A., Walsh C., Coen R., Coakley D., Lawlor B.A. Sleep disturbance in mild to moderate Alzheimer's disease. Sleep Medicine 2005, 6:347-352.
95. Murphy P.J., Badia P., Myers B.L., Boecker M.R., Wright K.P. Nonsteroidal anti-inflammatory drugs affect normal sleep patterns in humans. Physiology and Behavior 1994, 55:1063-1066.
96. Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
97. Ohashi Y., Okamoto N., Uchida K., Iyo M., Mori N., Morita Y. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biological Psychiatry 1999, 45:1646-1652.
98. Okawa M., Mishima K., Hishikawa Y., Hozumi S., Hori H., Takahashi K. Circadian rhythm disorders in sleep-waking and body temperature in elderly patients with dementia and their treatment. Sleep 1991, 14:478-485.
99. Olcese J.M., Cao C., Mori T., Mamcarz M.B., Maxwell A., Runfeldt M.J., Wang L., Zhang C., Lin X., Zhang G., Arendash G.W. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. Journal of Pineal Research 2009, 47:82-96.
100. Pandi-Perumal S.R., Srinivasan V., Maestroni G.J., Cardinali D.P., Poeggeler B., Hardeland R. Melatonin: nature's most versatile biological signal?. FEBS Journal 2006, 273:2813-2838.
101. Pandi-Perumal S.R., Zisapel N., Srinivasan V., Cardinali D.P. Melatonin and sleep in aging population. Experimental Gerontology 2005, 40:911-925.
102. Pappolla M., Bozner P., Soto C., Shao H., Robakis N.K., Zagorski M., Frangione B., Ghiso J. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. Journal of Biological Chemistry 1998, 273:7185-7188.
103. Pappolla M.A., Chyan Y.J., Poeggeler B., Frangione B., Wilson G., Ghiso J., Reiter R.J. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. Journal of Neural Transmission 2000, 107:203-231.
104. Pappolla M.A., Sos M., Omar R.A., Bick R.J., Hickson-Bick D.L., Reiter R.J., Efthimiopoulos S., Robakis N.K. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. Journal of Neuroscience 1997, 17:1683-1690.
105. Parvizi J., Van Hoesen G.W., Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer's disease. Annals of Neurology 2001, 49:53-66.
106. Pauley S.M. Lighting for the human circadian clock: recent research indicates that lighting has become a public health issue. Medical Hypotheses 2004, 63:588-596.
107. Peck J.S., LeGoff D.B., Ahmed I., Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. American Journal of Geriatric Psychiatry 2004, 12:432-436.
108. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nevsimalova S., Aldrich M., Reynolds D., Albin R., Li R., Hungs M., Pedrazzoli M., Padigaru M., Kucherlapati M., Fan J., Maki R., Lammers G.J., Bouras C., Kucherlapati R., Nishino S., Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Medicine 2000, 6:991-997.
109. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. Journal of Neuroscience 1998, 18:9996-10015.
110. Poceta J.S., Parsons L., Engelland S., Kripke D.F. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Medicine 2009, 10:129-133.
111. Poeggeler B., Miravalle L., Zagorski M.G., Wisniewski T., Chyan Y.J., Zhang Y., Shao H., Bryant-Thomas T., Vidal R., Frangione B., Ghiso J., Pappolla M.A. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry 2001, 40:14995-15001.
112. Pollak C.P., Perlick D. Sleep problems and institutionalization of the elderly. Journal of Geriatric Psychiatry and Neurology 1991, 4:204-210.
113. Prinz P.N., Peskind E.R., Vitaliano P.P., Raskind M.A., Eisdorfer C., Zemcuznikov N., Gerber C.J. Changes in the sleep and waking EEGs of nondemented and demented elderly subjects. Journal of the American Geriatrics Society 1982, 30:86-93.
114. Querfurth H.W., LaFerla F.M. Alzheimer's disease. New England Journal of Medicine 2010, 362:329-344.
115. Quinn J., Kulhanek D., Nowlin J., Jones R., Pratico D., Rokach J., Stackman R. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Research 2005, 1037:209-213.
116. Reiter R.J. The ageing pineal gland and its physiological consequences. Bioessays 1992, 14:169-175.
117. Reiter R.J., Calvo J.R., Karbownik M., Qi W., Tan D.X. Melatonin and its relation to the immune system and inflammation. Annals of the New York Academy of Sciences 2000, 917:376-386.
118. Reiter R.J., Tan D.X., Manchester L.C., El-Sawi M.R. Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging. Annals of the New York Academy of Sciences 2002, 959:238-250.
119. Reiter R.J., Tan D.X., Pappolla M.A. Melatonin relieves the neural oxidative burden that contributes to dementias. Annals of the New York Academy of Sciences 2004, 1035:179-196.
120. Reppert S.M., Weaver D.R. Coordination of circadian timing in mammals. Nature 2002, 418:935-941.
121. Reynolds C.F., Kupfer D.J., Taska L.S., Hoch C.C., Spiker D.G., Sewitch D.E., Zimmer B., Marin R.S., Nelson J.P., Martin D., et al. EEG sleep in elderly depressed, demented, and healthy subjects. Biological Psychiatry 1985, 20:431-442.
122. Riemersma-van der Lek R.F., Swaab D.F., Twisk J., Hol E.M., Hoogendijk W.J., Van Someren E.J. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA: The Journal of the American Medical Association 2008, 299:2642-2655.
123. Ripley B., Overeem S., Fujiki N., Nevsimalova S., Uchino M., Yesavage J., Di Monte D., Dohi K., Melberg A., Lammers G.J., Nishida Y., Roelandse F.W., Hungs M., Mignot E., Nishino S. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253-2258.
124. Sakurai T. Roles of orexins and orexin receptors in central regulation of feeding behavior and energy homeostasis. CNS & Neurological Disorders - Drug Targets 2006, 5:313-325.
125. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richarson J.A., Kozlowski G.P., Wilson S., Arch J.R., Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E., Liu W.S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92. 1 page following 696.
126. Sakurai T., Mieda M., Tsujino N. The orexin system: roles in sleep/wake regulation. Annals of the New York Academy of Sciences 2010, 1200:149-161.
127. Salomon R.M., Ripley B., Kennedy J.S., Johnson B., Schmidt D., Zeitzer J.M., Nishino S., Mignot E. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biological Psychiatry 2003, 54:96-104.
128. Saper C.B., Chou T.C., Scammell T.E. The sleep switch: hypothalamic control of sleep and wakefulness. Trends in Neurosciences 2001, 24:726-731.
129. Saper C.B., Fuller P.M., Pedersen N.P., Lu J., Scammell T.E. Sleep state switching. Neuron 2010, 68:1023-1042.
130. Saper C.B., Scammell T.E., Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
131. Satlin A., Volicer L., Stopa E.G., Harper D. Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease. Neurobiology of Aging 1995, 16:765-771.
132. Satomura T., Sakamoto T., Shirakawa S., Tsutsumi Y., Mukai M., Ohyama T., Uchimura N., Maeda H. Hypnotic action of melatonin during daytime administration and its comparison with triazolam. Psychiatry and Clinical Neurosciences 2001, 55:303-304.
133. Scammell T.E., Matheson J.K., Honda M., Thannickal T.C., Siegel J.M. Coexistence of narcolepsy and Alzheimer's disease. Neurobiology of Aging 2011, (Epub ahead of print).
134. Selkoe D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. Journal of Alzheimer's Disease 2001, 3:75-80.
135. Shen Y.X., Xu S.Y., Wei W., Wang X.L., Wang H., Sun X. Melatonin blocks rat hippocampal neuronal apoptosis induced by amyloid beta-peptide 25-35. Journal of Pineal Research 2002, 32:163-167.
136. Sherin J.E., Shiromani P.J., McCarley R.W., Saper C.B. Activation of ventrolateral preoptic neurons during sleep. Science 1996, 271:216-219.
137. Siegel J.M. Sleep viewed as a state of adaptive inactivity. Nature Reviews Neuroscience 2009, 10:747-753.
138. Singer C., Tractenberg R.E., Kaye J., Schafer K., Gamst A., Grundman M., Thomas R., Thal L.J. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003, 26:893-901.
139. Skene D.J., Swaab D.F. Melatonin rhythmicity: effect of age and Alzheimer's disease. Experimental Gerontology 2003, 38:199-206.
140. Skene D.J., Vivien-Roels B., Sparks D.L., Hunsaker J.C., Pevet P., Ravid D., Swaab D.F. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Research 1990, 528:170-174.
141. Slats D., Claassen J.A., Spies P.E., Borm G., Besse K.T., Aalst W.V., Tseng J., Sjogren M.J., Olde Rikkert M.G., Verbeek M.M. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiology of Aging 2012, 33(4):831.e1-831.e9.
142. Song W., Lahiri D.K. Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12. Journal of Molecular Neuroscience 1997, 9:75-92.
143. Song Y., Dowling G.A., Wallhagen M.I., Lee K.A., Strawbridge W.J. Sleep in older adults with Alzheimer's disease. Journal of Neuroscience Nursing 2010, 42:190-198. quiz 199-200.
144. Souetre E., Salvati E., Krebs B., Belugou J.L., Darcourt G. Abnormal melatonin response to 5-methoxypsoralen in dementia. American Journal of Psychiatry 1989, 146:1037-1040.
145. Srinivasan V., Pandi-Perumal S.R., Maestroni G.J., Esquifino A.I., Hardeland R., Cardinali D.P. Role of melatonin in neurodegenerative diseases. Neurotoxicity Research 2005, 7:293-318.
146. Stahl S.M., Markowitz J.S., Gutterman E.M., Papadopoulos G. Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. Journal of Clinical Psychiatry 2003, 64:466-472.
147. Sterniczuk R., Dyck R.H., Laferla F.M., Antle M.C. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 1. Circadian changes. Brain Research 2010, 1348:139-148.
148. Stopa E.G., Johnson J.K., Friedman D.I., Ryer H.I., Reidy J., Kuo-LeBlanc V., Albers H.E. Neuropeptide Y receptor distribution and regulation in the suprachiasmatic nucleus of the Syrian hamster (Mesocricetus auratus). Peptide Research 1995, 8:95-100.
149. Stopa E.G., Volicer L., Kuo-Leblanc V., Harper D., Lathi D., Tate B., Satlin A. Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia. Journal of Neuropathology and Experimental Neurology 1999, 58:29-39.
150. Surrall K., Smith J.A., Bird H., Okala B., Othman H., Padwick D.J. Effect of ibuprofen and indomethacin on human plasma melatonin. Journal of Pharmacy and Pharmacology 1987, 39:840-843.
151. Sutcliffe J.G., de Lecea L. The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. Journal of Neuroscience Research 2000, 62:161-168.
152. Swaab D.F., Fliers E., Partiman T.S. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Research 1985, 342:37-44.
153. Swaab D.F., Grundke-Iqbal I., Iqbal K., Kremer H.P., Ravid R., van de Nes J.A. Tau and ubiquitin in the human hypothalamus in aging and Alzheimer's disease. Brain Research 1992, 590:239-249.
154. Szymusiak R., Alam N., Steininger T.L., McGinty D. Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats. Brain Research 1998, 803:178-188.
155. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.
156. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., Cornford M., Siegel J.M. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
157. Thome J., Coogan A.N., Woods A.G., Darie C.C., Hassler F. CLOCK genes and circadian rhythmicity in Alzheimer disease. Journal of Aging Research 2011, 2011:383091.
158. Thompson R.H., Canteras N.S., Swanson L.W. Organization of projections from the dorsomedial nucleus of the hypothalamus: a PHA-L study in the rat. Journal of Comparative Neurology 1996, 376:143-173.
159. Tricoire H., Malpaux B., Moller M. Cellular lining of the sheep pineal recess studied by light-, transmission-, and scanning electron microscopy: morphologic indications for a direct secretion of melatonin from the pineal gland to the cerebrospinal fluid. Journal of Comparative Neurology 2003, 456:39-47.
160. Tzischinsky O., Shlitner A., Lavie P. The association between the nocturnal sleep gate and nocturnal onset of urinary 6-sulfatoxymelatonin. Journal of Biological Rhythms 1993, 8:199-209.
161. Uchida K., Okamoto N., Ohara K., Morita Y. Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Research 1996, 717:154-159.
162. van de Nes J.A., Kamphorst W., Ravid R., Swaab D.F. Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathologica 1998, 96:129-138.
163. van de Nes J.A., Sluiter A.A., Pool C.W., Kamphorst W., Ravid R., Swaab D.F. The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas. Brain Research 1994, 655:97-109.
164. van den Pol A.N., Ghosh P.K., Liu R.J., Li Y., Aghajanian G.K., Gao X.B. Hypocretin (orexin) enhances neuron activity and cell synchrony in developing mouse GFP-expressing locus coeruleus. The Journal of Physiology 2002, 541:169-185.
165. Van Someren E.J. Circadian rhythms and sleep in human aging. Chronobiology International 2000, 17:233-243.
166. Vitiello M.V., Bliwise D.L., Prinz P.N. Sleep in Alzheimer's disease and the sundown syndrome. Neurology 1992, 42:83-93. discussion 93-84.
167. Vitiello M.V., Prinz P.N., Williams D.E., Frommlet M.S., Ries R.K. Sleep disturbances in patients with mild-stage Alzheimer's disease. Journal of Gerontology 1990, 45:M131-M138.
168. Volicer L., Harper D.G., Manning B.C., Goldstein R., Satlin A. Sundowning and circadian rhythms in Alzheimer's disease. American Journal of Psychiatry 2001, 158:704-711.
169. Wade A.G., Ford I., Crawford G., McMahon A.D., Nir T., Laudon M., Zisapel N. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion 2007, 23:2597-2605.
170. Wang J.Z., Wang Z.F. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacologica Sinica 2006, 27:41-49.
171. Weldemichael D.A., Grossberg G.T. Circadian rhythm disturbances in patients with Alzheimer's disease: a review. International Journal of Alzheimer's Disease 2010, 2010.
172. Wu Y.H., Feenstra M.G., Zhou J.N., Liu R.Y., Torano J.S., Van Kan H.J., Fischer D.F., Ravid R., Swaab D.F. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. Journal of Clinical Endocrinology and Metabolism 2003, 88:5898-5906.
173. Wu Y.H., Fischer D.F., Kalsbeek A., Garidou-Boof M.L., van der Vliet J., van Heijningen C., Liu R.Y., Zhou J.N., Swaab D.F. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the " master clock" FASEB Journal 2006, 20:1874-1876.
174. Wu Y.H., Swaab D.F. The human pineal gland and melatonin in aging and Alzheimer's disease. Journal of Pineal Research 2005, 38:145-152.
175. Wu Y.H., Swaab D.F. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Medicine 2007, 8:623-636.
176. Wurtman R.J. Narcolepsy and the hypocretins. Metabolism: Clinical and Experimental 2006, 55:S36-S39.
177. Yaffe K., Laffan A.M., Harrison S.L., Redline S., Spira A.P., Ensrud K.E., Ancoli-Israel S., Stone K.L. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA: The Journal of the American Medical Association 2011, 306:613-619.
178. Yamanaka A., Beuckmann C.T., Willie J.T., Hara J., Tsujino N., Mieda M., Tominaga M., Yagami K., Sugiyama F., Goto K., Yanagisawa M., Sakurai T. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003, 38:701-713.
179. Yesavage J.A., Friedman L., Ancoli-Israel S., Bliwise D., Singer C., Vitiello M.V., Monjan A.A., Lebowitz B. Development of diagnostic criteria for defining sleep disturbance in Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 2003, 16:131-139.
180. Yoshida Y., Fujiki N., Nakajima T., Ripley B., Matsumura H., Yoneda H., Mignot E., Nishino S. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. European Journal of Neuroscience 2001, 14:1075-1081.
181. Zhdanova I.V. Sleep and its regulation in zebrafish. Reviews in the Neurosciences 2011, 22:27-36.
182. Zhou J.N., Hofman M.A., Swaab D.F. VIP neurons in the human SCN in relation to sex, age, and Alzheimer's disease. Neurobiology of Aging 1995, 16:571-576.
183. Zhou J.N., Liu R.Y., Kamphorst W., Hofman M.A., Swaab D.F. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. Journal of Pineal Research 2003, 35:125-130.
184. Zhu L.Q., Wang S.H., Ling Z.Q., Wang D.L., Wang J.Z. Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. Journal of Pineal Research 2004, 37:71-77.
185. Zieba D.A., Klocek B., Williams G.L., Romanowicz K., Boliglowa L., Wozniak M. In vitro evidence that leptin suppresses melatonin secretion during long days and stimulates its secretion during short days in seasonal breeding ewes. Domestic Animal Endocrinology 2007, 33:358-365.
186. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cellular and Molecular Neurobiology 2001, 21:605-616.